The stock has a 36-month beta value of 0.75. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for AGIO is 55.15M, and at present, short sellers hold a 6.27% of that float. On August 29, 2024, the average trading volume of AGIO was 699.51K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AGIO) stock’s latest price update
The stock price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) has dropped by -3.67 compared to previous close of 47.09. Despite this, the company has seen a fall of -3.69% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-27 that Agios’ Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd’s label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025.
AGIO’s Market Performance
AGIO’s stock has fallen by -3.69% in the past week, with a monthly drop of -3.06% and a quarterly rise of 19.37%. The volatility ratio for the week is 5.05% while the volatility levels for the last 30 days are 4.62% for Agios Pharmaceuticals Inc The simple moving average for the last 20 days is 1.07% for AGIO’s stock, with a simple moving average of 38.47% for the last 200 days.
Analysts’ Opinion of AGIO
Piper Sandler, on the other hand, stated in their research note that they expect to see AGIO reach a price target of $41. The rating they have provided for AGIO stocks is “Overweight” according to the report published on February 03rd, 2023.
Goldman gave a rating of “Neutral” to AGIO, setting the target price at $32 in the report published on November 17th of the previous year.
AGIO Trading at 0.75% from the 50-Day Moving Average
After a stumble in the market that brought AGIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.91% of loss for the given period.
Volatility was left at 4.62%, however, over the last 30 days, the volatility rate increased by 5.05%, as shares sank -2.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.50% upper at present.
During the last 5 trading sessions, AGIO fell by -3.69%, which changed the moving average for the period of 200-days by +112.36% in comparison to the 20-day moving average, which settled at $44.83. In addition, Agios Pharmaceuticals Inc saw 103.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGIO starting from Goff Brian, who sale 11,091 shares at the price of $42.75 back on Aug 08 ’24. After this action, Goff Brian now owns 78,792 shares of Agios Pharmaceuticals Inc, valued at $474,140 using the latest closing price.
Goff Brian, the Officer of Agios Pharmaceuticals Inc, proposed sale 11,091 shares at $42.75 during a trade that took place back on Aug 08 ’24, which means that Goff Brian is holding shares at $474,184 based on the most recent closing price.
Stock Fundamentals for AGIO
Current profitability levels for the company are sitting at:
- -12.94 for the present operating margin
- 0.75 for the gross margin
The net margin for Agios Pharmaceuticals Inc stands at -11.66. The total capital return value is set at -0.57. Equity return is now at value -44.92, with -39.28 for asset returns.
Based on Agios Pharmaceuticals Inc (AGIO), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -4.74.
Currently, EBITDA for the company is -384.86 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 81.8. The receivables turnover for the company is 8.32for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.09.
Conclusion
To sum up, Agios Pharmaceuticals Inc (AGIO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
